Literature DB >> 26082935

Chronic sustained inflammation links to left ventricular hypertrophy and aortic valve sclerosis: a new link between S100/RAGE and FGF23.

Ling Yan1, Marion A Hofmann Bowman1.   

Abstract

BACKGROUND: Cardiovascular disease including left ventricular hypertrophy, diastolic dysfunction and ectopic valvular calcification are common in patients with chronic kidney disease (CKD). Both S100A12 and fibroblast growth factor 23 (FGF23) have been identified as biomarkers of cardiovascular morbidity and mortality in patients with CKD. We tested the hypothesis that human S100/calgranulin would accelerate cardiovascular disease in mice subjected to CKD.
METHODS: This review paper focuses on S100 proteins and their receptor for advanced glycation end products (RAGE) and summarizes recent findings obtained in novel developed transgenic hBAC-S100 mice that express S100A12 and S100A8/9 proteins. A bacterial artificial chromosome of the human S100/calgranulin gene cluster containing the genes and regulatory elements for S100A8, S100A9 and S100A12 was expressed in C57BL/6J mice (hBAC-S100). CKD was induced by ureteral ligation, and hBAC-S100 mice and WT mice were studied after 10 weeks of chronic uremia.
RESULTS: hBAC-S100 mice with CKD showed increased FGF23 in the heart, left ventricular hypertrophy (LVH), diastolic dysfunction, focal cartilaginous metaplasia and calcification of the mitral and aortic valve annulus together with aortic valve sclerosis. This phenotype was not observed in WT mice with CKD or in hBAC-S100 mice lacking RAGE with CKD, suggesting that the inflammatory milieu mediated by S100/RAGE promotes pathological cardiac hypertrophy in CKD. In vitro, inflammatory stimuli including IL-6, TNFα, LPS, or serum from hBAC-S100 mice up regulated FGF23 mRNA and protein in primary murine neonatal and adult cardiac fibroblasts.
CONCLUSIONS: Taken together, our study shows that myeloid-derived human S100/calgranulin is associated with the development of cardiac hypertrophy and ectopic cardiac calcification in a RAGE dependent manner in a mouse model of CKD. We speculate that FGF23 produced by cardiac fibroblasts in response to cytokines may act in a paracrine manner to accelerate LVH and diastolic dysfunction in hBAC-S100 mice with CKD. We suggest that S100/RAGE-mediated chronic sustained systemic inflammation is linked to pathological cardiac remodeling via direct up regulation of FGF23 in cardiac fibroblasts, thereby providing a new mechanistic understanding for the common association between CKD, diabetes, metabolic syndrome, or hypertension with left ventricular hypertrophy with diastolic dysfunction.

Entities:  

Keywords:  Chronic kidney disease; Ectopic cardiac calcification; Fibroblast growth factor 23 (FGF23); Left ventricular hypertrophy; Receptor for advanced glycation end products (RAGE); S100 proteins

Year:  2014        PMID: 26082935      PMCID: PMC4465803          DOI: 10.14800/ics.279

Source DB:  PubMed          Journal:  Inflamm Cell Signal        ISSN: 2330-7803


  50 in total

1.  Multicenter validation of the diagnostic accuracy of a blood-based gene expression test for assessing obstructive coronary artery disease in nondiabetic patients.

Authors:  Steven Rosenberg; Michael R Elashoff; Philip Beineke; Susan E Daniels; James A Wingrove; Whittemore G Tingley; Philip T Sager; Amy J Sehnert; May Yau; William E Kraus; L Kristin Newby; Robert S Schwartz; Szilard Voros; Stephen G Ellis; Naeem Tahirkheli; Ron Waksman; John McPherson; Alexandra Lansky; Mary E Winn; Nicholas J Schork; Eric J Topol
Journal:  Ann Intern Med       Date:  2010-10-05       Impact factor: 25.391

2.  High levels of S100A12 are associated with recent plaque symptomatology in patients with carotid atherosclerosis.

Authors:  Azhar Abbas; Pål Aukrust; Tuva B Dahl; Vigdis Bjerkeli; Ellen B Lund Sagen; Annika Michelsen; David Russell; Kirsten Krohg-Sørensen; Kirsten Krohg Sørensen; Sverre Holm; Mona Skjelland; Bente Halvorsen
Journal:  Stroke       Date:  2012-03-01       Impact factor: 7.914

3.  S100A12 is expressed exclusively by granulocytes and acts independently from MRP8 and MRP14.

Authors:  T Vogl; C Pröpper; M Hartmann; A Strey; K Strupat; C van den Bos; C Sorg; J Roth
Journal:  J Biol Chem       Date:  1999-09-03       Impact factor: 5.157

4.  Activation of the ROCK1 branch of the transforming growth factor-beta pathway contributes to RAGE-dependent acceleration of atherosclerosis in diabetic ApoE-null mice.

Authors:  De-xiu Bu; Vivek Rai; Xiaoping Shen; Rosa Rosario; Yan Lu; Vivette D'Agati; Shi Fang Yan; Richard A Friedman; Edem Nuglozeh; Ann Marie Schmidt
Journal:  Circ Res       Date:  2010-02-04       Impact factor: 17.367

5.  Vascular and inflammatory stresses mediate atherosclerosis via RAGE and its ligands in apoE-/- mice.

Authors:  Evis Harja; De-xiu Bu; Barry I Hudson; Jong Sun Chang; Xiaoping Shen; Kellie Hallam; Anastasia Z Kalea; Yan Lu; Rosa H Rosario; Sai Oruganti; Zana Nikolla; Dmitri Belov; Evanthia Lalla; Ravichandran Ramasamy; Shi Fang Yan; Ann Marie Schmidt
Journal:  J Clin Invest       Date:  2008-01       Impact factor: 14.808

6.  IL-10-dependent S100A8 gene induction in monocytes/macrophages by double-stranded RNA.

Authors:  Yasumi Endoh; Yuen Ming Chung; Ian A Clark; Carolyn L Geczy; Kenneth Hsu
Journal:  J Immunol       Date:  2009-02-15       Impact factor: 5.422

7.  Serum S100A12 concentrations are correlated with angiographic coronary lesion complexity in patients with coronary artery disease.

Authors:  Jun Liu; Yin-Gang Ren; Li-Hua Zhang; Ya-Wen Tong; Li Kang
Journal:  Scand J Clin Lab Invest       Date:  2013-12-16       Impact factor: 1.713

8.  Pleiotropic roles of S100A12 in coronary atherosclerotic plaque formation and rupture.

Authors:  Jesse Goyette; Wei Xing Yan; Eric Yamen; Yuen Ming Chung; Su Yin Lim; Kenneth Hsu; Farid Rahimi; Nick Di Girolamo; Changjie Song; Wendy Jessup; Maaike Kockx; Yuri V Bobryshev; S Ben Freedman; Carolyn L Geczy
Journal:  J Immunol       Date:  2009-07-01       Impact factor: 5.422

9.  FGF-23 is associated with increased disease severity and early mortality in cardiogenic shock.

Authors:  Janine Pöss; Felix Mahfoud; Sarah Seiler; Gunnar H Heine; Danilo Fliser; Michael Böhm; Andreas Link
Journal:  Eur Heart J Acute Cardiovasc Care       Date:  2013-09

10.  Plasma S100A12 levels and peripheral arterial disease in end-stage renal disease.

Authors:  Yayoi Shiotsu; Yasukiyo Mori; Tsuguru Hatta; Noboru Maki; Kumiko Iida; Eiko Matsuoka; Hiroshi Kado; Ryo Ishida; Noriko Kishimoto; Keiichi Tamagaki; Masato Nishimura; Noriyuki Iwamoto; Toshihiko Ono; Hiroaki Matsubara; Atsushi Kosaki
Journal:  Nephron Extra       Date:  2011-12-21
View more
  14 in total

1.  Histopathological assessment of calcification and inflammation of calcific aortic valves from patients with and without diabetes mellitus.

Authors:  Josephin Mosch; Christian A Gleissner; Simon Body; Elena Aikawa
Journal:  Histol Histopathol       Date:  2016-06-29       Impact factor: 2.303

Review 2.  Ironing out the cross talk between FGF23 and inflammation.

Authors:  Valentin David; Connor Francis; Jodie L Babitt
Journal:  Am J Physiol Renal Physiol       Date:  2016-08-31

Review 3.  Cardiac actions of fibroblast growth factor 23.

Authors:  Christian Faul
Journal:  Bone       Date:  2016-10-07       Impact factor: 4.398

Review 4.  Inflammation regulates fibroblast growth factor 23 production.

Authors:  Connor Francis; Valentin David
Journal:  Curr Opin Nephrol Hypertens       Date:  2016-07       Impact factor: 2.894

5.  Increased Levels of sRAGE in Diabetic CKD-G5D Patients: A Potential Protective Mechanism against AGE-Related Upregulation of Fibroblast Growth Factor 23 and Inflammation.

Authors:  Elena Dozio; Valentina Corradi; Elena Vianello; Elisa Scalzotto; Massimo de Cal; Massimiliano Marco Corsi Romanelli; Claudio Ronco
Journal:  Mediators Inflamm       Date:  2017-09-25       Impact factor: 4.711

6.  Interleukin-1 inhibition, chronic kidney disease-mineral and bone disorder, and physical function
.

Authors:  Kristen L Nowak; Adriana Hung; Talat Alp Ikizler; Heather Farmer-Bailey; Natjalie Salas-Cruz; Sudipa Sarkar; Andrew Hoofnagle; Zhiying You; Michel Chonchol
Journal:  Clin Nephrol       Date:  2017-09       Impact factor: 0.975

7.  Genetic Ablation of Fgf23 or Klotho Does not Modulate Experimental Heart Hypertrophy Induced by Pressure Overload.

Authors:  Svetlana Slavic; Kristopher Ford; Magalie Modert; Amarela Becirovic; Stephan Handschuh; Andreas Baierl; Nejla Katica; Ute Zeitz; Reinhold G Erben; Olena Andrukhova
Journal:  Sci Rep       Date:  2017-09-12       Impact factor: 4.379

8.  FGF23 promotes myocardial fibrosis in mice through activation of β-catenin.

Authors:  Huixin Hao; Xixian Li; Qingman Li; Hairuo Lin; Zhenhuan Chen; Jiahe Xie; Wanling Xuan; Wangjun Liao; Jianping Bin; Xiaobo Huang; Masafumi Kitakaze; Yulin Liao
Journal:  Oncotarget       Date:  2016-10-04

Review 9.  Paracrine Effects of FGF23 on the Heart.

Authors:  Maren Leifheit-Nestler; Dieter Haffner
Journal:  Front Endocrinol (Lausanne)       Date:  2018-05-28       Impact factor: 5.555

Review 10.  FGF23 Actions on Target Tissues-With and Without Klotho.

Authors:  Beatrice Richter; Christian Faul
Journal:  Front Endocrinol (Lausanne)       Date:  2018-05-02       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.